2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Cannabis Science Congratulates and Welcomes the State of Pennsylvania as the 24th State to Legalize Medical Cannabis

Cannabis Science Congratulates and Welcomes the State of Pennsylvania as the 24th State to Legalize Medical Cannabis

COLORADO SPRINGS, CO--(Marketwired - Apr 18, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is proud to extend its congratulations to the State of Pennsylvania as the 24th state to legalize cannabis for medical purposes.

On Sunday, April 17, 2016, the Governor of Pennsylvania signed into law Senate Bill 3, legalizing medical cannabis consumption. Pennsylvania represents the 24th state to pass such legislation. The U.S. is nearly halfway to full medical legalization. As more states legalize medical cannabis, research and clinical trials can become simpler and less expensive to initiate and maintain.

"While we don't currently have operations in Pennsylvania, we are certainly expecting a few calls to come in. We are excited to have the option to explore potential partnerships and research opportunities there in the future," said Director, President, CEO & Co-Founder, Raymond C. Dabney. "On behalf of our company and the medical cannabis industry as a whole, we would like to extend a warm welcome to the new patients that the SB3 bill will benefit."

The bill received 149 votes in favor and 46 votes opposing legalizing medical cannabis in a Republican-controlled House. The landslide victory on this bill shows even many of the more conservative politicians are opening their minds to the potential lifesaving properties of cannabis as another viable medical treatment.

Related links:

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.